After Alexion buyout, AstraZeneca pays Roche $775M to settle Ultomiris patent brawlnews2022-03-17T12:53:09+00:00March 17th, 2022|Fierce Pharma|
Catalent completes $30M expansion at French site, adding capacity and 80 jobsnews2022-03-17T12:25:44+00:00March 17th, 2022|Fierce Pharma|
Bristol Myers’ Opdivo combo Opdualag scores FDA approval in melanoma, opens 3rd immune checkpoint drug classnews2022-03-17T10:26:44+00:00March 17th, 2022|Fierce Pharma|
BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: reportnews2022-03-16T17:19:29+00:00March 16th, 2022|Fierce Pharma|
AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine warnews2022-03-16T15:18:15+00:00March 16th, 2022|Fierce Pharma|
Lilly and Boehringer’s Jardiance, trailing AZ’s Farxiga in chronic kidney disease, posts efficacy winnews2022-03-16T14:27:14+00:00March 16th, 2022|Fierce Pharma|
Former J&J CEO Alex Gorsky saw total pay fall last year but remains among pharma’s best-paidnews2022-03-16T14:27:01+00:00March 16th, 2022|Fierce Pharma|
Biogen piles on more long-term Aduhelm data, linking biomarker to Alzheimer’s clinical benefitnews2022-03-16T13:59:09+00:00March 16th, 2022|Fierce Pharma|
Consent At Scale: A Permission-Based Marketing Frameworknews2022-03-16T13:30:26+00:00March 16th, 2022|Fierce Pharma|
Biotech execs who pinched Genentech trade secrets headed to prisonnews2022-03-16T13:27:11+00:00March 16th, 2022|Fierce Pharma|
